ASX:IDX

Integral Diagnostics Competitors

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume240,828 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend Yield1.96%

BetaN/A

Integral Diagnostics (ASX:IDX) Vs. BUX, IME, BD1, CRL, CTE, and DVL

Should you be buying IDX stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to Integral Diagnostics, including (BUX) (BUX), 12144 (IME), BARD1 Life Sciences (BD1), Charles River Laboratories International (CRL), Cryosite (CTE), and dorsaVi (DVL).

Integral Diagnostics vs. (BUX) Stock

Integral Diagnostics (ASX:IDX) and (BUX) (CNSX:BUX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares Integral Diagnostics and (BUX)'s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integral Diagnostics	$314.82 million	0.00	$32.18 million	A$0.16	N/A
(BUX)	N/A	N/A	N/A	N/A	N/A

Integral Diagnostics has higher revenue and earnings than (BUX).

Profitability

This table compares Integral Diagnostics and (BUX)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integral Diagnostics	N/A	N/A	N/A
(BUX)	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations for Integral Diagnostics and (BUX), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integral Diagnostics	0	0	0	0	N/A
(BUX)	0	0	0	0	N/A

Summary

Integral Diagnostics beats (BUX) on 1 of the 1 factors compared between the two stocks.

Integral Diagnostics vs. 12144 Stock

12144 (CNSX:IME) and Integral Diagnostics (ASX:IDX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Analyst Ratings

This is a breakdown of recent recommendations for 12144 and Integral Diagnostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
12144	0	0	0	0	N/A
Integral Diagnostics	0	0	0	0	N/A

Profitability

This table compares 12144 and Integral Diagnostics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
12144	N/A	N/A	N/A
Integral Diagnostics	N/A	N/A	N/A

Earnings & Valuation

This table compares 12144 and Integral Diagnostics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
12144	N/A	N/A	N/A	N/A	N/A
Integral Diagnostics	$314.82 million	0.00	$32.18 million	A$0.16	N/A

Integral Diagnostics has higher revenue and earnings than 12144.

Summary

Integral Diagnostics beats 12144 on 1 of the 1 factors compared between the two stocks.

Integral Diagnostics vs. BARD1 Life Sciences Stock

BARD1 Life Sciences (ASX:BD1) and Integral Diagnostics (ASX:IDX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Valuation & Earnings

This table compares BARD1 Life Sciences and Integral Diagnostics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BARD1 Life Sciences	$612,251.00	0.00	$-6,644,706.43	A($0.08)	N/A
Integral Diagnostics	$314.82 million	0.00	$32.18 million	A$0.16	N/A

Integral Diagnostics has higher revenue and earnings than BARD1 Life Sciences.

Profitability

This table compares BARD1 Life Sciences and Integral Diagnostics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BARD1 Life Sciences	N/A	N/A	N/A
Integral Diagnostics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for BARD1 Life Sciences and Integral Diagnostics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BARD1 Life Sciences	0	0	0	0	N/A
Integral Diagnostics	0	0	0	0	N/A

Summary

Integral Diagnostics beats BARD1 Life Sciences on 3 of the 3 factors compared between the two stocks.

Integral Diagnostics vs. Charles River Laboratories International Stock

Charles River Laboratories International (CNSX:CRL) and Integral Diagnostics (ASX:IDX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Valuation & Earnings

This table compares Charles River Laboratories International and Integral Diagnostics' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	N/A	N/A	N/A	N/A	N/A
Integral Diagnostics	$314.82 million	0.00	$32.18 million	A$0.16	N/A

Integral Diagnostics has higher revenue and earnings than Charles River Laboratories International.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Charles River Laboratories International and Integral Diagnostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	0	0	0	0	N/A
Integral Diagnostics	0	0	0	0	N/A

Profitability

This table compares Charles River Laboratories International and Integral Diagnostics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	N/A	N/A	N/A
Integral Diagnostics	N/A	N/A	N/A

Summary

Integral Diagnostics beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

Integral Diagnostics vs. Cryosite Stock

Integral Diagnostics (ASX:IDX) and Cryosite (ASX:CTE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Valuation & Earnings

This table compares Integral Diagnostics and Cryosite's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integral Diagnostics	$314.82 million	0.00	$32.18 million	A$0.16	N/A
Cryosite	$9.71 million	0.00	$515,455.60	A$0.01	N/A

Integral Diagnostics has higher revenue and earnings than Cryosite.

Profitability

This table compares Integral Diagnostics and Cryosite's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integral Diagnostics	N/A	N/A	N/A
Cryosite	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings for Integral Diagnostics and Cryosite, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integral Diagnostics	0	0	0	0	N/A
Cryosite	0	0	0	0	N/A

Summary

Integral Diagnostics beats Cryosite on 3 of the 3 factors compared between the two stocks.

Integral Diagnostics vs. dorsaVi Stock

Integral Diagnostics (ASX:IDX) and dorsaVi (ASX:DVL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Earnings and Valuation

This table compares Integral Diagnostics and dorsaVi's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integral Diagnostics	$314.82 million	0.00	$32.18 million	A$0.16	N/A
dorsaVi	$1.65 million	0.00	$-3,158,396.93	A($0.01)	N/A

Integral Diagnostics has higher revenue and earnings than dorsaVi.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Integral Diagnostics and dorsaVi, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integral Diagnostics	0	0	0	0	N/A
dorsaVi	0	0	0	0	N/A

Profitability

This table compares Integral Diagnostics and dorsaVi's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integral Diagnostics	N/A	N/A	N/A
dorsaVi	N/A	N/A	N/A

Summary

Integral Diagnostics beats dorsaVi on 3 of the 3 factors compared between the two stocks.